EBV-associated malignancies

Open Infectious Diseases Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 101-112

  Ocheni, S ^a   Olusina, D B ^b   Oyekunle, A A ^c   Ibegbulam, O G ^a   Kroger N ^d   Bacher, U ^d   Zander, A R ^d  

^a University of Nigeria Enugu Campus   (Nigeria)

^b UNIVERSITY OF NIGERIA   (Nigeria)

^c OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Association; Epstein barr virus; Malignancies; Targeted therapy

Indexed keywords

BUTYRIC ACID; CYCLIN DEPENDENT KINASE 4; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; GANCICLOVIR; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD70; MYC PROTEIN; ONCOLYTIC VIRUS; PREDNISONE; RITUXIMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE IMMUNOTHERAPY; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CARCINOGENESIS; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 8; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; ELECTRON MICROSCOPY; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; GENE EXPRESSION PROFILING; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEIC ACID AMPLIFICATION; ONCOLYTIC VIROTHERAPY; ORGAN TRANSPLANTATION; PERSISTENT INFECTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; SOUTHERN BLOTTING; STOMACH CARCINOMA; VIRUS CULTURE;

HUMAN HERPESVIRUS 4;

EID: 78249245430     PISSN: None     EISSN: 18742793     Source Type: Journal    
DOI: 10.2174/1874279301004020101     Document Type: Article

References (112)

1. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000; 21: 405-26.
2. Martin GS. The road to Src. Oncogene 2004; 23: 7910-7.
3. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968; 59: 94-101.
4. Kutok JL, Wang FW. Spectrum of epstein-barr virus-associated diseases. Annu Rev Pathol Mech Dis 2006; 1: 375-404.
5. Gruhne B, Sompallae R, Masucci MG. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 2009; 28(45): 3999-4008.
6. Raptis S, Bapat B. Genetic instability in human tumors. EXS 2006; 96: 303-20.
7. Stollmann B, Fonatsch C, Havers W. Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders Br J Haematol 1985; 60: 183-196.
8. Klein G. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors. AIDS Res 1986; 2(Suppl 1):; S167-S76.
9. Karlsson QH, Schelcher C, Verrall E, Petosa C, Sinclair AJ. The reversal of epigenetic silencing of the EBV genome is regulated by viral bZIP protein. Biochem Soc Trans 2008; 36: 637-9.
10. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, Eds. Fields Virology, 3rd ed. Philadelphia: Lipincott-Raven Publishers 1996; pp. 2343-96.
11. Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol Mol Pathol 2000; 53: 238-47.
12. Borish B, Raphael M, Swerdlow SH et al. Lymphoproliferative diseases associated with primary immune disorders. In Jaffe ES, Harris NL, Stein H, et al., Eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001; pp. 257-9.
13. Carbone A, Gloghini A, Dotti G. EBV-Associated lymphoproliferative disorders: Classification and Treatment. The Oncologist 2008; 13: 577-85.
14. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-9.
15. Cohen JI. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol 2003; 40: 116-23.
16. Hsieh WS, Lemas MV, Ambinder RF. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease. Transplant Infect Dis 1999; 1: 204-12.
17. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: Interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transplant Infect Dis 2001; 3: 60-9.
18. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803-21.
19. Davis JE, Sherritt MA, Bharadwaj M et al. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD. Int Immunol 2004; 16: 983-9.
20. Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review J Clin Pathol 2000; 53: 248-54.
21. Wagner HJ, Bein G, Bitsch A, et al. Detection and quantitation of latently infected B-lymphocytes in Epstein-Barr virus seropositive healthy individuals by polymerase chain reaction. J Clin Microbiol 1992; 30: 2826-9.
22. Preiksaitis JK, Diaz-Mitoma F, Mirazayans F, et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serological responses, and the risk of post-transplant lymphoproli-ferative disorder. J Infect Dis 1992; 166: 986-94.
23. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus-infected lymphocytes and decreased Epstein-Barr virus nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease n solid organ transplant recipients. Blood 1994; 84: 972-84.
24. Cen H, Breining MC, Atchison RW, et al. Epstein-Barr virus transmission via donor organs. J Virol 1991; 65: 976-80.
25. Haque T, Thomas JA, Falk KI, et al. Transmission of donor Epstein-Barr virus in transplanted organs causes lymphoproliferative disease in EBV seronegative recipients. J Gen Virol 1996; 77: 1169-72.
26. Penn I. The problem of cancer in organ transplant recipients: an overview. Transplant Sci 1994; 4: 23-32.
27. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus-associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 72: 1234-43.
28. Rea D, Fourcade C, Leblond V, et al. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994; 58: 317-24.
29. Hunt BJ, Thomas JA, Burke M. Epstein-Barr virus associated Burkitt's lymphoma in a heart transplant recipient. Transplantation 1996; 62. 869-72.
30. Raphael MM, Audouin J, Lamine M, et al. Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors. Am J Clin Pathol 1994; 101: 773-82.
31. Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immuno-deficiency virus associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol 1998; 16: 3788-95.
32. Diebold J, Raphael M, Prevot S, Audouin J. Lymphomas associated with HIV infection. Cancer Surv 1997; 30: 263-93.
33. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumours occurring after organ transplantation. N Engl J Med 1995; 332: 19-25.
34. McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995; 332: 12-18.
35. Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J 2008; 84: 372-7.
36. Eisenman RN. Deconstructing myc. Genes Dev 2001; 15: 2023-30.
37. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19: 158-64.
38. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46: 218-23.
39. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 2007; 7: 166-75.
40. Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J 2008; 84: 372-7.
41. Wright DH. Burkitt's lymphoma: a review of the pathology, immunology, and possible etiologic factors. Pathol Annu 1971; 6: 337-63.
42. Ho M, Webster HK, Green B, Looareesuwan S, Kongchareon S, White NJ. Defective production of and response to IL 2 in acute human falciparum malaria. J Immunol 1988; 141. 2755-9.
43. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18. 3707-21.
44. Gutierrez MI, Bhatia K, Barriga F, et al. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 1992; 79: 3261-6.
45. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, Eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC press 2001; pp 181-4.
46. Parkin DM, Ferlay J, Hamdi-Cherif M, et al. Cancer in Africa. Lyon: IARC Scientific Publications 2003; 153.
47. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 2008; 6: 913-24.
48. Wright, DH. The epidemiology of Burkitt's tumor. Cancer Res 1967; 27: 2424-38.
49. Deyrup AT. Epstein-Barr virus associated epithelial and mesenchymal neoplasms. Hum Pathol 2008; 39: 473-83.
50. Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: More questions than answers. Int J Cancer 2009; 124: 1745-55.
51. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990; 55: 133-270.
52. Klein G. Specific chromosomal translocations and the genesis of B cell-derived tumors in mice and men. Cell 1983; 32: 311-15.
53. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 1986; 47: 11-18.
54. Zhu D, Qi CF, Morse HC, III, Janz S, Stevenson FK. Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. Blood 2005; 105: 2135-7.
55. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res 1966; 26: 1189-1200.
56. Levine PH, Ablashi DV, Berard CW, Carbone PP, Waggoner DE, Malan L. Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer 1971; 27: 416-21.
57. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989; 320: 689-95.
58. Gutensohn N, Cole P. Epidemiology of Hodgkin's disease. Semin Oncol 1980; 7: 92-102.
59. Weiss LM, Chen Y-Y, Liu X-F, et al. Epstein-Barr virus and Hodgkin's disease: a correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991; 139: 1259-65.
60. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993; 177: 339-49.
61. Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 1990; 46: 801-4.
62. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989; 74: 810-6.
63. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16: 471-93.
64. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9: 405-11.
65. Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood 1992; 80: 484-91.
66. Hummel M, Anagnostopoulos I, Dallenbach F, et al. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of gene products. Br J Haematol 1992; 82: 689-94.
67. Chang KL, Albujar PF, Chen Y-Y, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993; 81: 496-501.
68. Jarrett AF, Armstrong AA, Alexander E. Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 1996; 7(Suppl 4): 5-10.
69. Weinreb M, Day PJR, Niggli F, et al. The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 1996; 87: 3828-36.
70. Weinreb M, Day PJR, Niggli F, et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child 1996; 74: 27-31.
71. Baumforth KR, Young LS, Flavell KJ, et al. The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999; 52: 307-22.
72. Crawford DH. Biology and disease associations of Epstein - Barr virus. Phil Trans R Soc Lond 2001; 356: 461-73.
73. Leung SY, Chung LP, Yuen ST, Ho CM, Wong MP, Chan SY. Lymphoepithelial carcinoma of the salivary gland: in situ detection of Epstein-Barr virus. J Clin Pathol 1995; 48: 1022-7.
74. Gullo C, Low WK. Teoh G. Association of Epstein-Barr Virus with Nasopharyngeal Carcinoma and Current Status of Development of Cancer-derived Cell Lines. Ann Acad Med Singapore 2008; 37: 769-77.
75. Ballinger JR, Li JH. Sestamibi accumulation in human nasopharyngeal carcinoma cell lines in vitro. Anticancer Res 2000; 20: 677-9.
76. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 17: 481-92.
77. Huang ES, Gutsch D, Tzung KW, Lin CT. Detection of low level of human papilloma virus type 16 DNA sequences in cancer cell lines derived from two well-differentiated nasopharyngeal cancers. J Med Virol 1993; 40: 244-50.
78. Charfi S, Khabir A, Ayadi L, et al. Expression of c-kit in North African nasopharyngeal carcinomas: correlation with age and LMP1. Cancer Radiother 2007; 11: 247-51.
79. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol Mol Pathol 2000; 53: 248-54.
80. Yu MC. Diet and nasopharyngeal carcinoma. FEMS Microbiol Immunol 1990; 2: 235-42.
81. Yu MC. Nasopharyngeal carcinoma: epidemiology and dietary factors. IARC Sci Publ 1991; (105): 39-47.
82. Poirier S, Ohshima H, de The G, Hubert A, Bourgade MC. Bartsch H. Volatile nitrosamine levels in common foods from Tunisia, south China and Greenland, high-risk areas for nasopharyngeal carcinoma (NPC). Int J Cancer 1987; 39: 293-6.
83. Wu YT, Luo HL, Johnson DR. Effect of nickel sulfate on cellular proliferation and Epstein-Barr virus antigen expression in lymphoblastoid cell lines. Cancer Lett 1986; 32: 171-9.
84. Morrison JA, Raab-Traub N. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol 2005; 79: 2375-82.
85. Heussinger N, Buttner M, Ott G, Brachtel E, Pilch BZ, et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV associated nasopharyngeal carcinoma. J Pathol 2004; 203: 696-9.
86. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333: 693-8.
87. Niedobitek G, Fahraeus R, Herbst H, et al. The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1992; 62: 55-9.
88. Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69: 1051-65.
89. Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M. Epstein-Barr virus is associated with gastric carcinoma: The question is what is the significance? World J Gastroenterol 2008.14: 4347-51.
90. Uemura Y, Tokunaga M, Arikawa J et al. A unique morphology of Epstein-Barr virus-related early gastric carcinoma. Cancer Epidemiol Biomarkers Prev 1994 3: 607-11.
91. Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci 2008; 99: 1726-1733.
92. Takada K. Epstein-Barr virus and gastric carcinoma. J Clin Pathol Mol Pathol 2000; 53: 255-61.
93. Koriyama C, Akiba S, Minakami Y, Eizuru Y. Environmental factors related to Epstein-Barr virus-associated gastric cancer in Japan. J Exp Clin Cancer Res 2005; 24: 547-53.
94. Gulley ML. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 2001; 3: 1-10.
95. Brousset P, Butet V, Chittal S, Selves J, Delsol G. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohisto-chemical correlation with anti-latent membrane protein antibody. Lab Invest 1992; 67: 457-64.
96. Lones MA, Shintaku IP, Weiss LM, Thung SN, Nichols WS, Geller SA. Posttransplant lymphoproliferative disorder in liver allograft biopsies: a comparison of three methods for the demonstration of Epstein-Barr virus. Hum Pathol 1997; 28: 533-9.
97. Shibata D, Weiss LM, Nathwani BN, Brynes RK, Levine AM. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma. Blood 1991; 77: 1527-33.
98. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 singlephoton emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999; 17: 554-60.
99. Bai X, Hosler G, Rogers BB, Dawson DB, Scheuermann RH. Quantitative polymerase chain reaction for human herpesvirus diagnosis and measurement of Epstein-Barr virus burden in posttransplant lymphoproliferative disorder. Clin Chem 1997; 43: 1843-9.
100. Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452-5.
101. Svahn A, Magnusson M, Jagdahl L, Schloss L, Kahlmeter G, Linde A. Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection. J Clin Microbiol 1997; 35: 2728-32.
102. Deng H, Zeng Y, Lei Y, et al. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J 1995; 108: 300-3.
103. Choquet S, Trappe R, Leblond V et al. CHOP-21 for the treatment of posttransplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-4.
104. Gross TG, Bucuvalas JC, Park JR et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23: 6481-8.
105. Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis J Biol Chem 2009; 284: 17102-9.
106. Kenney S. Development of novel, EBV-targeted therapies for EBV-positive tumors. Transactions of the American Clinical and Climatological Association 2006; Vol. 117: 55-74.
107. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002; 62: 1920-6.
108. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-8.
109. Ambinder RF. Epstein-barr virus and hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007: 204-9.
110. Heslop HE, Slobod KS, Pule MA et al. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients, Blood 2010; 115: 925-35.
111. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592-8.
112. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy for Epstein-Barr Virus-Associated Cancers. Monogr Natl Cancer Inst 1998; 23: 89-93.